New radiotracer aims to spot hidden cancers

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with diagnosed or suspected tumors visiting the hospital between January 2026 and December 2026, who are scheduled for pathological biopsy or surgical treatment within 2 months. 2. Age \> 18 years, regardless of gender. 3. Adequate organ and bone marrow function as defined by the following laboratory values: * Hematology: WBC ≥4.0×10\^9/L or ANC ≥1.5×10\^9/L; PLT ≥100×10\^9/L; Hemoglobin ≥90 g/L. * Liver Function: Total bilirubin ≤1.5× ULN; ALT and AST ≤2.5× ULN (or ≤5× ULN if liver metastases are present). * Renal Function: BUN ≤1.5× ULN; Serum Creatinine (SCr) ≤1.5× ULN. 4. Normal cardiac function. 5. Expected life expectancy ≥12 weeks. 6. Presence of at least one measurable target lesion according to RECIST v1.1 criteria. 7. Patients recommended by clinicians to undergo PET/CT examination for tumor diagnosis and staging. 8. Women of childbearing potential must have a negative pregnancy test within 7 days prior to the examination. Male and female patients of reproductive age must agree to use effective contraception during the study and for at least 3 months after the examination. 9. Voluntarily participate in the study, demonstrate full understanding of the protocol, and provide written informed consent. Exclusion Criteria: 1. Severe laboratory abnormalities, including significant impairment of hepatic or renal function, or severe hematological dysfunction. 2. History of allergic diseases. 3. Patients planning for pregnancy during the study period. 4. Pregnant or lactating women. 5. Inability to maintain a supine position for at least 30 minutes. 6. Patients with claustrophobia or other diagnosed psychiatric disorders that may interfere with compliance. 7. Any other condition that, in the opinion of the investigator, may increase the risk to the subject or interfere with the evaluation of the study results.